AI Article Synopsis
- The study investigates the effectiveness of various biomarkers for diagnosing and predicting outcomes in acutely dyspnoeic patients aged under and over 75.
- Both younger (<75 years) and older (≥75 years) patients exhibited high diagnostic performance from natriuretic peptides, particularly BNP, which achieved an area under the curve (AUC) of 0.98 in both groups.
- Galectin-3 was found to be the most effective prognostic biomarker for predicting one-year mortality in both age groups, with AUCs of 0.74 for old and 0.75 for young patients.
Article Abstract
Background: Acute dyspnoea is the leading cause of unscheduled admission of elderly patients. Several biomarkers are used to diagnose acute heart failure (AHF) and assess prognosis of dyspnoeic patients, but their value in elderly patients is unclear.
Objective: To compare diagnostic and prognostic performances of conventional and novel cardiovascular biomarkers in 2 age groups: young (<75 years old) vs. old (≥75 years old) dyspnoeic patients.
Design: Prospective observational registry.
Setting: Emergency department (ED).
Subjects: Acutely dyspnoeic adult patients.
Methods: Blood samples were collected at ED admission. The diagnostic value of 4 natriuretic peptides (BNP, proBNP, NT-proBNP, MR-proANP) for AHF was tested. We also assessed the prognostic value of same natriuretic peptides and of 3 novel cardiovascular biomarkers (galectin-3, sST2 and proenkephalin), using 1-year all-cause mortality as end-point. Diagnostic or prognostic performances are expressed as area under the receiveroperating characteristic curve (AUC) with 95% confidence interval.
Results: Two hundred one acutely dyspnoeic patients were studied. AHF was the cause of dyspnoea in 57% of old and 44% of young patients, respectively. All 4 natriuretic peptides performed well in diagnosing AHF in both age groups (all AUC>0.7). BNP showed the best diagnostic performance in both old (AUC: 0.98 [0.97-1.00]) and young (AUC 0.98 [0.95-1.00]) patients. Galectin-3 showed the best prognostic performance in both old (AUC 0.74 [0.62-0.87]) and young patients (AUC 0.75 [0.56-0.94]).
Conclusions: BNP and galectin-3 show good clinical benefits in both oldand young acutely dyspnoeic patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.archger.2016.08.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!